Kubota Y, Nakada T, Suzuki Y, Iizima Y, Adachi Y, Hashimoto T
Department of Urology, Yamagata University School of Medicine, Japan.
Int Urol Nephrol. 1993;25(5):469-74.
From 1981 to 1989, 24 patients with newly diagnosed metastatic prostate cancer received hormone chemotherapy consisting of orchiectomy, diethylstilbestrol diphosphate and cisplatin. The survival rates were compared with those of 17 metastatic prostate cancer patients who were treated with hormone therapy alone. The five-year survival rates for the hormone chemotherapy group and the hormone therapy group were 64.6% and 29.4%, respectively. Based on our findings, it seems likely that hormone chemotherapy is one of the most effective treatments for patients with newly diagnosed metastatic prostate cancer.
1981年至1989年期间，24例新诊断为转移性前列腺癌的患者接受了由睾丸切除术、己烯雌酚二磷酸酯和顺铂组成的激素化疗。将其生存率与17例仅接受激素治疗的转移性前列腺癌患者的生存率进行比较。激素化疗组和激素治疗组的五年生存率分别为64.6%和29.4%。根据我们的研究结果，激素化疗似乎是新诊断为转移性前列腺癌患者最有效的治疗方法之一。
